Welcome to our dedicated page for ABPRO HLDGS news (Ticker: ABP), a resource for investors and traders seeking the latest updates and insights on ABPRO HLDGS stock.
Abpro Corporation (ABP) is a clinical-stage biotech company developing novel antibody therapies for cancer and eye diseases. This page aggregates official news and regulatory filings related to their therapeutic pipeline, strategic partnerships, and corporate developments.
Investors and researchers will find timely updates on clinical trial progress for lead candidates including ABP-102 (HER2+ cancers) and ABP-201 (macular degeneration). The repository includes SEC filings, partnership announcements with organizations like Celltrion, and manufacturing updates.
Key content types include: clinical trial milestones, regulatory submissions, intellectual property developments, and financial reporting. All materials are sourced from official company communications to ensure reliability.
Bookmark this page for consolidated access to Abpro's latest scientific advancements and corporate news. Check back regularly for updates on their Nasdaq listing progress and pipeline expansion.
Abpro Holdings (Nasdaq: ABP) has announced an upcoming oral presentation of preclinical data for their drug candidate ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-Cell Engager, at the AACR Annual Meeting 2025. The presentation will take place during the New Drugs on the Horizon session at McCormick Place Convention Center in Chicago, between April 25-30.
The company, which focuses on developing next-generation antibody therapies for severe and life-threatening diseases, has established a strategic partnership with Celltrion for the worldwide development and commercialization of ABP-102/CT-P72.
Abpro Holdings (Nasdaq:ABP) announced the departure of CEO Ian Chan, with Board Chairman Miles Suk assuming the CEO position. The company emphasized that this leadership transition will not impact their strategic direction or stability.
The company reaffirmed its commitment to ABP 102/CT-P72, their joint development project with Celltrion. Chief Medical Officer Robert J. Markelewicz highlighted that initial data indicates ABP-102/CT-P72 could be potentially best-in-class for HER2-positive cancers, which affect up to 30% of breast, gastric, pancreatic, and other cancer cases. Additional data will be presented at an upcoming scientific meeting in spring.
Abpro Holdings (Nasdaq:ABP) celebrated its business combination closure with Atlantic Coastal Acquisition Corp II through a Nasdaq bell ringing ceremony. The company raised $10 million in gross proceeds, including a $7 million PIPE offering and $2.76 million convertible note financing.
Additional financing arrangements include a $50 million standby equity purchase agreement with Yorkville, potential for $2 million in additional debt financing, and a forward purchase agreement for up to 500,000 shares of common stock. These funds will support Abpro's development of next-generation antibody therapies for cancer, ophthalmology, and infectious diseases.
The company has partnered with Celltrion to advance ABP 102, a T-cell engager for treating HER2+ breast, gastric, and pancreatic cancers. Abpro's pipeline focuses on multiple cancer types, wet age-related macular degeneration (AMD), and diabetic macular edema (DME), utilizing their proprietary DiversImmune® platform.
